Rapport Therapeutics, Inc. (RAPP)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $87k
- Sep 23 · Routine
- Form 4 sales
- 42
- On record
- Form 144 notices
- 0
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineJul 14 2026
Sold 8,210 shares at $40.00 ($328k)
Ceesay Abraham, Chief Executive Officer
10b5-1 planSold 1.5% of holdings ($21.9M position)539,817 shares left0.8x usual sizeFiling
- 2 Form 4 saleRoutineJul 27 +13 days
Sold 2,210 shares at $42.11 ($93k)
Ceesay Abraham, Chief Executive Officer
10b5-1 planSold 0.4% of holdings ($22.7M position)537,607 shares left0.2x usual sizeFiling
- 3 Form 4 saleUnusualAug 11 +15 days
Sold 51,499 shares at $47.24 ($2.4M)
Ceesay Abraham, Chief Executive Officer
10b5-1 planSold 9.6% of holdings ($25.4M position)486,108 shares left4.7x usual sizeFiling
- 4 Form 4 saleRoutineAug 19 +8 days
Sold 404 shares at $49.90 ($20k)
Yeleswaram Krishnaswamy, Chief Development Officer
10b5-1 planSold 0.2% of holdings ($12.3M position)246,022 shares left0x usual sizeFiling
- 5 Form 4 saleUnusualAug 25 +6 days
Sold 50,160 shares at $50.47 ($2.5M)
Yeleswaram Krishnaswamy, Chief Development Officer
10b5-1 planSold 20.4% of holdings ($12.4M position)195,862 shares left7.7x usual sizeFiling
- 6 Form 4 saleRoutineAug 25 same day
Sold 18,921 shares at $49.57 ($938k)
Ceesay Abraham, Chief Executive Officer
10b5-1 planSold 3.9% of holdings ($24.1M position)467,187 shares left1.7x usual sizeFiling
- 7 Form 4 saleRoutineSep 8 +14 days
Sold 8,210 shares at $45.62 ($375k)
Ceesay Abraham, Chief Executive Officer
10b5-1 planSold 1.8% of holdings ($21.3M position)458,977 shares left0.8x usual sizeFiling
- 8 Form 4 saleRoutineSep 23 +15 days
Sold 2,210 shares at $39.17 ($87k)
Ceesay Abraham, Chief Executive Officer
10b5-1 planSold 0.5% of holdings ($18M position)456,767 shares left0.2x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (42)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 2,210 | $87k | 0.5% | Routine | SEC |
| Sep 8, 2026 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 8,210 | $375k | 1.8% | Routine | SEC |
| Aug 25, 2026 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 18,921 | $938k | 3.9% | Routine | SEC |
| Aug 25, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | Form 4 sale | 50,160 | $2.5M | 20.4% | Unusual | SEC |
| Aug 19, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | Form 4 sale | 404 | $20k | 0.2% | Routine | SEC |
| Aug 11, 2026 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 51,499 | $2.4M | 9.6% | Unusual | SEC |
| Jul 27, 2026 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 2,210 | $93k | 0.4% | Routine | SEC |
| Jul 14, 2026 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 8,210 | $328k | 1.5% | Routine | SEC |
| Jun 30, 2026 | Gault Cheryl | Chief Operating Officer | Form 4 sale | 10,000 | $416k | 6.3% | Routine | SEC |
| Jun 29, 2026 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 8,220 | $327k | 1.5% | Routine | SEC |
| May 26, 2026 | Third Rock Ventures V, L.P. | 10% owner | Form 4 sale | 18,572 | $744k | 0.3% | Routine | SEC |
| May 11, 2026 | Third Rock Ventures V, L.P. | 10% owner | Form 4 sale | 133,618 | $5.4M | 2.1% | Routine | SEC |
| May 8, 2026 | Third Rock Ventures VI, L.P. | 10% owner | Form 4 sale | 276,513 | $11.1M | 4.1% | Routine | SEC |
| Apr 17, 2026 | Third Rock Ventures VI, L.P. | 10% owner | Form 4 sale | 426,005 | $17.2M | 6.0% | Routine | SEC |
| Apr 17, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | Form 4 sale | 20,225 | $809k | 7.6% | Unusual | SEC |
| Apr 14, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | Form 4 sale | 19,865 | $696k | 6.9% | Unusual | SEC |
| Apr 8, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | Form 4 sale | 360 | $13k | 0.1% | Routine | SEC |
| Mar 30, 2026 | Gault Cheryl | Chief Operating Officer | Form 4 sale | 10,000 | $282k | 5.9% | Routine | SEC |
| Mar 25, 2026 | Yeleswaram Krishnaswamy | Chief Development Officer | Form 4 sale | 10,115 | $303k | 3.4% | Routine | SEC |
| Mar 5, 2026 | Gault Cheryl | Chief Operating Officer | Form 4 sale | 2,014 | $58k | 1.2% | No plan | SEC |
| Feb 18, 2026 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 10,916 | $320k | 1.9% | Routine | SEC |
| Feb 17, 2026 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $247k | 2.1% | Routine | SEC |
| Jan 20, 2026 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 10,916 | $285k | 1.9% | Routine | SEC |
| Jan 15, 2026 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $228k | 2.1% | Routine | SEC |
| Dec 31, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 6,567 | $197k | 1.6% | No plan | SEC |
| Dec 31, 2025 | Yeleswaram Krishnaswamy | Chief Development Officer | Form 4 sale | 2,840 | $85k | 0.9% | No plan | SEC |
| Dec 17, 2025 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 10,916 | $324k | 1.9% | Routine | SEC |
| Dec 15, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $255k | 2.1% | Routine | SEC |
| Nov 26, 2025 | Gault Cheryl | Chief Operating Officer | Form 4 sale | 5,000 | $151k | 2.8% | Routine | SEC |
| Nov 17, 2025 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 10,916 | $275k | 1.9% | Routine | SEC |
| Nov 17, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $214k | 2.1% | Routine | SEC |
| Oct 15, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $219k | 2.0% | Routine | SEC |
| Oct 15, 2025 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 10,916 | $282k | 1.8% | Routine | SEC |
| Sep 17, 2025 | Ceesay Abraham | Chief Executive Officer | Form 4 sale | 76,420 | $2M | 11.5% | Routine | SEC |
| Sep 15, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $206k | 2.0% | Routine | SEC |
| Sep 8, 2025 | Gault Cheryl | Chief Operating Officer | Form 4 sale | 5,000 | $192k | 2.8% | Routine | SEC |
| Aug 15, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $127k | 2.0% | Routine | SEC |
| Jul 15, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $119k | 1.9% | Routine | SEC |
| Jun 16, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $94k | 1.9% | Routine | SEC |
| May 15, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $81k | 1.8% | Routine | SEC |
| Apr 15, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $81k | 1.8% | Routine | SEC |
| Mar 14, 2025 | Bredt David | Chief Scientific Officer | Form 4 sale | 8,500 | $92k | 1.8% | Routine | SEC |